Eldessouki Ihab, Gaber Ola, Riaz Muhammad K, Wang Jiang, Abdel Karim Nagla
Department of Hematology- Oncology, Vontz Center for molecular studies, University of Cincinnati, OH,USA. Email:
Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2373-2376. doi: 10.22034/APJCP.2018.19.9.2373.
Clear cell carcinomas are common finding in renal, ovarian and uterine carcinomas. However, clear cell lung cancer (CCLC), first described by Liebow and Castleman in 1963, is considered an extremely rare variant of lung tumors. The 2011 WHO classification of lung tumors considered CCLC as a rare cytologic feature of squamous cell or adenocarcinomas. It is no longer recognized as a formal subtype, albeit it can be referred to in the pathological diagnosis as “with clear cell features” even with marginal fractions of the tumor cells. Such recognition is needed since the variation in clinical features and outcome in this subset of patients. The disease has a clinically vague natural history, is characterized by slight female predominance and is often seen in the elderly. As frequently encountered with rare diseases, its clinical course and treatment options have many questions still yet to be answered. In this paper, we review both the natural history and treatment options mentioned in literature, in the light of our experience by reporting a case series of four patients diagnosed with CCLC and highlight their aspects.
透明细胞癌在肾癌、卵巢癌和子宫癌中很常见。然而，透明细胞肺癌（CCLC）于1963年由利博（Liebow）和卡斯尔曼（Castleman）首次描述，被认为是一种极其罕见的肺肿瘤变体。2011年世界卫生组织（WHO）的肺肿瘤分类将CCLC视为鳞状细胞癌或腺癌的一种罕见细胞学特征。它不再被视为一种正式的亚型，尽管即使肿瘤细胞只有少量，在病理诊断中也可将其称为“具有透明细胞特征”。由于该亚组患者临床特征和预后存在差异，因此需要这种识别。该疾病临床自然史不明确，女性略占优势，且常见于老年人。与罕见疾病常见情况一样，其临床病程和治疗选择仍有许多问题有待解答。在本文中，我们根据对4例诊断为CCLC患者的病例系列经验，回顾文献中提到的自然史和治疗选择，并突出其中要点。
